Journal Article

Enteroviral Meningoencephalitis after Anti-CD20 (Rituximab) Treatment

Pierre Quartier, Olivier Tournilhac, Christine Archimbaud, Leila Lazaro, Carine Chaleteix, Pascale Millet, Hélène Peigue-Lafeuille, Stéphane Blanche, Alain Fischer, Jean-Laurent Casanova, Philippe Travade and Marc Tardieu

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 3, pages e47-e49
Published in print February 2003 | ISSN: 1058-4838
Published online February 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/345746
Enteroviral Meningoencephalitis after Anti-CD20 (Rituximab) Treatment

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.

Journal Article.  1881 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.